Advertisement

Chromatographia

, Volume 81, Issue 3, pp 525–531 | Cite as

Separation and Characterization of New Forced Degradation Products of Macitentan: A Dual Endothelin Receptor Antagonist

  • Mohit Thummar
  • Debasish Swain
  • S. GananadhamuEmail author
Short Communication

Abstract

Macitentan (MCT) is an endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension. In the present study, MCT was subjected to forced degradation as per ICH guidelines. The drug degraded extensively in acidic, basic as well as neutral hydrolytic conditions and seven degradation products (DPs) were formed. All these DPs were selectively separated using high-performance liquid chromatography (HPLC) with a stationary phase of Inertsil C18 column (150 × 4.6 mm, 5 μm) and a mobile phase consisting of gradient mixture of 0.02% trifluoroacetic acid (TFA) and acetonitrile (ACN). The developed HPLC method was transferred to LC–ESI–QTOF–MS/MS for identification of DPs. The final mass spectrometric conditions were optimized for better ionization of drug and DPs with optimum mass signal sensitivity. All the formed DPs were new and well separated with sufficient resolution. The developed HPLC method was validated as per ICH-guidelines and can be used in drug testing labs for determination of quality of MCT in bulk and finished formulations.

Keywords

Macitentan Stability indicating assay method Forced degradation LC–ESI–QTOF–MS/MS 

Notes

Acknowledgements

The authors would like to show appreciation towards the National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, and the Ministry of Chemicals and Fertilizers, New Delhi, India, for providing a facilities and research fellowship.

Compliance with Ethical Standards

Conflict of interest

Authors Mohit Thummar, Debasish Swain and Dr. S. Gananadhamu have declared that they have no conflict of interest.

Human/animal studies

This article does not contain any studies related to human, animal or biological materials.

Supplementary material

10337_2018_3471_MOESM1_ESM.tif (581 kb)
Supplementary material 1 (TIFF 580 kb)
10337_2018_3471_MOESM2_ESM.tif (387 kb)
Supplementary material 2 (TIFF 387 kb)
10337_2018_3471_MOESM3_ESM.tif (624 kb)
Supplementary material 3 (TIFF 623 kb)
10337_2018_3471_MOESM4_ESM.tif (948 kb)
Supplementary material 4 (TIFF 947 kb)
10337_2018_3471_MOESM5_ESM.docx (13 kb)
Supplementary material 5 (DOCX 13 kb)
10337_2018_3471_MOESM6_ESM.docx (26 kb)
Supplementary material 6 (DOCX 25 kb)
10337_2018_3471_MOESM7_ESM.docx (12 kb)
Supplementary material 7 (DOCX 11 kb)

References

  1. 1.
    Iglarz Marc, Binkert Christoph, Morrison Keith, Fischli Walter, Gatfield John, Treiber Alexander, Weller Thomas, Bolli Martin H, Boss Christoph, Buchmann Stephan, Capeleto Bruno, Hess Patrick, Qiu Changbin, Clozel Martine (2008) J Pharmacol Exp Ther 327:736–745CrossRefGoogle Scholar
  2. 2.
    Bakshi M, Singh S (2002) J Pharm Biomed Anal 28:1011–1040CrossRefGoogle Scholar
  3. 3.
    Swain D, Patel PN, Nagaraj G et al (2016) Chromatographia 79:169–178CrossRefGoogle Scholar
  4. 4.
    Singh S, Handa T, Narayanam M, Sahu A, Junwal M, Shah RP (2012) J Pharm Biomed Anal 69:148–173CrossRefGoogle Scholar
  5. 5.
    Thummar M, Patel PN, Petkar AL, Swain D, Srinivas R, Gananadhamu S (2017) Rapid Commun Mass Spectrom 31:771–781CrossRefGoogle Scholar
  6. 6.
    Vishnuvardhan C, Swain D, Borkar R et al (2016) Chromatographia 79:1293–1308CrossRefGoogle Scholar
  7. 7.
    Pandeti Sukanya, Narender Tadigoppula, Prabhakar Sripadi (2017) Thota Jagadeswar Reddy. Rapid Commun Mass Spectrom 31:572–582CrossRefGoogle Scholar
  8. 8.
    Namdev D, Borkar RM, Raju B, Kalariya PD, Rahangdale VT, Gananadhamu S, Srinivas R (2014) J Pharm Biomed Anal 88:245–255CrossRefGoogle Scholar
  9. 9.
    Thummar M, Patel PN, Gananadhamu S, Srinivas R (2017) Rapid Commun Mass Spectrom.  https://doi.org/10.1002/rcm.7968 Google Scholar
  10. 10.
    Unnisa Aziz, Ali Syed Sadath, Santosh Kumar S (2014) Indo Am J Pharm Res 4(09):3836–3843Google Scholar
  11. 11.
    Yua Lixiu, Zhoua Ying, He Xiaomeng, Li Huqun, Chenb Hui, Li Weiyong (2015) J Chromatogr B 1002:358–363CrossRefGoogle Scholar
  12. 12.
    Sidharta PN, Treiber A, Dingemanse J (2015) Clin Pharmacokinet 54:457–471CrossRefGoogle Scholar
  13. 13.
    ICH (1996) Photo stability testing of new drug substances and products, Q1B. In: International conference on harmonisation (ICH). IFPMA, GenevaGoogle Scholar
  14. 14.
    ICH (2005) Validation of analytical procedures: text and methodology, Q2 (R1). In: International conference on harmonisation (ICH), GenevaGoogle Scholar
  15. 15.
    US Pharmacopeia 24 (2013) Validation of compendia methods, section 〈1223〉. United States Pharmacopeial Convention, Rockville, p 979Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pharmaceutical AnalysisNational Institute of Pharmaceutical Education and Research (NIPER)HyderabadIndia

Personalised recommendations